Akari Therapeutics reiterates commitment to research on PH1

Akari Therapeutics (AKTX) reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator, PH1, having demonstrated it may also act to inhibit key drivers in cancer tumors. Akari’s ADCs utilize its novel spliceosome modulator payload, PH1, and have the potential to significantly improve future oncology therapies based on current preclinical data demonstrating the following: Killing cancer cells while activating the immune system: In addition to killing cancer cells, spliceosome modulation by the PH1 payload causes the accumulation of mis-spliced proteins, generating neoantigens that activate the immune system to further attack the cancer tumor. Reducing off-target toxicity: Linker is engineered to only release PH1 payload intracellularly within targeted cancer cells to mitigate off-target toxicity. Circumventing traditional cancer resistance mechanisms: PH1 is resistant to standard efflux transporters that can cause cancer cells to become resistant to current payloads used on ADCs. Akari continues to build on this key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for cancer cell growth. Preliminary data from additional preclinical research experiments testing activity of PH1 against an established oncogenic driver unique to a major tumor are expected before year-end.